Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07ESC
|
|||
| Former ID |
DCL000699
|
|||
| Drug Name |
Apremilast
|
|||
| Synonyms |
Apremilast (USAN); CC-10004; N-[2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethyl]-1,3-dioxo-isoindol-4-yl]acetamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Psoriasis vulgaris [ICD-11: EA90; ICD-9: 696] | Approved | [1], [2] | |
| Company |
Celgene
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H24N2O7S
|
|||
| Canonical SMILES |
CCOC1=C(C=CC(=C1)C(CS(=O)(=O)C)N2C(=O)C3=C(C2=O)C(=CC=C3)NC(=O)C)OC
|
|||
| InChI |
1S/C22H24N2O7S/c1-5-31-19-11-14(9-10-18(19)30-3)17(12-32(4,28)29)24-21(26)15-7-6-8-16(23-13(2)25)20(15)22(24)27/h6-11,17H,5,12H2,1-4H3,(H,23,25)/t17-/m1/s1
|
|||
| InChIKey |
IMOZEMNVLZVGJZ-QGZVFWFLSA-N
|
|||
| CAS Number |
CAS 608141-41-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
16663888, 28672022, 42703565, 50086920, 78553422, 96025543, 103594774, 104103394, 135195808, 135299279, 136946493, 140792549, 144115618, 152256090, 152258393, 160647230, 164045129, 164194075, 176253765, 178103944, 186014493, 187575333, 189561506, 198938842, 198994002, 218902332, 223380767, 223443866, 223593318, 224603101, 226643371, 247101845, 249492055, 249814467, 250163167, 251962967, 251970550, 252088578, 252160602, 252214744, 252438251, 252451837, 252553654
|
|||
| ChEBI ID |
CHEBI:78540
|
|||
| ADReCS Drug ID | BADD_D00156 | |||
| SuperDrug ATC ID |
L04AA32
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7372). | |||
| REF 2 | Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63. | |||
| REF 3 | Agreement signed with Prostagenics to develop prostate cancer treatment. Innovate Oncology, Inc. 2005. | |||
| REF 4 | Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets. 2007 Mar;6(1):17-26. | |||
| REF 5 | CC-10004 . Curr Opin Investig Drugs. 2005 May;6(5):518-25. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.